Cite
HARVARD Citation
, . et al. (2022). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet infectious diseases. 22 (5), pp. 622-635. [Online].